Cara Therapeutics Inc (CARA) Given Average Recommendation of “Buy” by Brokerages
Shares of Cara Therapeutics Inc (NASDAQ:CARA) have been assigned an average recommendation of “Buy” from the seventeen brokerages that are presently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation, nine have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $25.75.
Several research analysts have recently weighed in on CARA shares. Scotiabank upped their price target on shares of Cara Therapeutics from $31.00 to $31.50 and gave the stock an “outperform” rating in a report on Tuesday, October 17th. ValuEngine cut shares of Cara Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, September 27th. BidaskClub raised shares of Cara Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, December 2nd. Raymond James Financial upped their target price on shares of Cara Therapeutics from $25.00 to $26.00 and gave the stock a “market perform” rating in a research report on Tuesday, November 7th. Finally, Zacks Investment Research lowered shares of Cara Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, October 4th.
In related news, CEO Derek T. Chalmers sold 16,000 shares of the company’s stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $12.66, for a total value of $202,560.00. Following the completion of the transaction, the chief executive officer now directly owns 1,066,292 shares in the company, valued at $13,499,256.72. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 7.50% of the stock is currently owned by insiders.
Cara Therapeutics (CARA) opened at $12.43 on Tuesday. The firm has a market cap of $405.32, a price-to-earnings ratio of -5.43 and a beta of 2.96. Cara Therapeutics has a 1-year low of $10.25 and a 1-year high of $28.50.
Cara Therapeutics (NASDAQ:CARA) last released its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.03). During the same period in the previous year, the company earned ($0.42) EPS. equities analysts predict that Cara Therapeutics will post -1.84 earnings per share for the current fiscal year.
Cara Therapeutics Company Profile
Cara Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. It is developing a class of product candidates that target the body’s peripheral nervous system.
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.